High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.
L C Costello, T E Hartman, J H Ryu
https://pubmed.ncbi.nlm.nih.gov/10852420/Actively Recruiting
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-10-29
100
Participants Needed
1
Research Sites
N/A
Total Duration
Lymphangioleiomyomatosis LAM is a rare lung disease that mainly affects women, causing muscle tissue to grow in the lungs and block airflow. This progressive disease can lead to severe breathing problems and may even require a lung transplant. Researchers are evaluating whether inhaled albuterol delivered by a nebulizer or a metered dose inhaler MDI better improves lung function in women with LAM. Participants in this study will be randomly assigned to receive albuterol either via a nebulizer or through two or four puffs of a metered dose inhaler across three consecutive days. The study includes a 3-day overnight stay during which treatments are administered around the same time each day. Higher doses of albuterol than usual are tested with the inhaler. Lung function tests are performed before and after each treatment to measure changes. Women aged 18 and older with impaired lung function due to LAM will be involved. Screening includes a physical exam and medical history, and participants must stop long-acting inhalers one week before the study. Researchers will track lung function improvements over the 3 days to compare the two delivery methods. The primary outcome is the difference in lung function after treatment. The total study period extends until November 2027.
CONDITIONS
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
T
Tatyana A Worthy, R.N.
J
Joel Moss, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Heart, Lung, and Blood Institute (NHLBI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Albuterol by Nebulizer | Albuterol by Inhaler |
|---|---|---|
| What it is | Albuterol (a bronchodilator) delivered as a mist through a nebulizer device for acute bronchodilation. | Albuterol (a bronchodilator) delivered by metered-dose inhaler for acute bronchodilation. |
| Role in Trial | Investigational intervention to assess whether nebulizer delivery produces greater improvement in lung function compared to inhaler delivery. | Active comparator arm to evaluate bronchodilator response using standard inhaler-based albuterol delivery. |
| Primary Use | Relief of airflow obstruction and improvement of lung function in LAM by delivering aerosolized albuterol directly to the lungs. | Relief of airflow obstruction and improvement of lung function via inhaled albuterol in women with LAM. |
| How it is given or performed | Albuterol is given as an aerosolized solution through a nebulizer for inhalation, usually in a clinical or home setting. | Albuterol is delivered as measured doses by a metered-dose inhaler, intended for inhalation and rapid bronchodilation. |
| Evidence Status | No comparative published trials establish superiority of nebulized albuterol over inhaler for LAM. Ongoing trial investigation. | Limited published evidence supports use of inhaled albuterol for short-term bronchodilation in LAM with variable response rates. |
| Important Limitations | Nebulizer devices require more time, equipment, and supervision than inhalers; individual variability in bronchodilator response among LAM patients. | Proper inhaler technique is necessary for effectiveness; not all LAM patients experience improved airflow with inhaled bronchodilators. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility with a physical exam and medical history to confirm they can join the trial.
1 visit
Duration - 3 days
Participants stay overnight for 3 days at the study site and receive albuterol either by nebulizer or inhaler each day. Lung function tests are done before and after each treatment to measure breathing improvements.
Daily visits during overnight stay
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
L C Costello, T E Hartman, J H Ryu
https://pubmed.ncbi.nlm.nih.gov/10852420/Jay H Ryu, Joel Moss, Gerald J Beck...
https://pubmed.ncbi.nlm.nih.gov/16210669/Francis X McCormack
https://pubmed.ncbi.nlm.nih.gov/18252917/National Heart, Lung, and Blood Institute (NHLBI)
Lead Sponsor